

FY26 Results & FY27 Outlook

From Repositioning to Growth

Jeremy Steele, CEO

28 August 2026

DISCLAIMER

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

Certain information may relate to protected intellectual property rights owned by Control Bionics Limited (Control Bionics) and its subsidiaries (together the Group).

While due care has been taken in compiling the information based on the information available to Control Bionics at the date of the presentation material, neither Control Bionics nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Group.

The information does not constitute advice of any kind and should not be relied upon as such. Investors must make their own independent assessment of the Group and undertake such additional enquiries as they deem necessary or appropriate for the own investment purposes. Any and all use of the information is at your own risk.

No representations, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by and person (including Control Bionics). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumptions or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based.

Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, Control Bionics disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations to any forward looking statements or any change in events, conditions or circumstances on which and such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of the Group since the date of these materials.

FY26 Repositioned the Business for a New Commercial Model

FY26 – Foundation Established

- Shift from direct retail to wholesale/distribution
- US distribution partnerships established
- NeuroNode reimbursement and European market pathways progressed
- NDIS approval delays constrained Australian revenue
- NeuroStrip expanded into new markets and applications
- NeuroBounce acquired and integrated
- Balance sheet strengthened through capital raising

FY27 – Commercialisation

- Scale US wholesale distribution
- Launch NextLevel iOS device
- Expand NeuroStrip commercialisation
- Build recurring commercial channels grow related revenue
- Progress platform-led growth strategy



FY26 Financial Results

	FY26 (\$ m)	FY25 (\$ m)	Change
Revenue	4.8	6.1	(22.4%)
Net loss after tax	(7.3)	(6.1)	18.9%
Net assets (30 June)	6.3	5.5	14.6%
Cash	2.1	0.6	249%
Net tangible assets per share (cents)	0.44	0.55	(20%)
Net operating cash flow	(5.7)	(4.3)	34.7%

Revenue Impact

- US transition from direct retail to distributor -led wholesale
- NDIS approval delays had material impact

Investment


- Continued R&D investment
- NeuroBounce acquisition and integration
- NeuroStrip Launch

Cost Discipline

- Total expenses ↓ 5.1%
- Travel ↓ 24.4%

Additional Context:

\$9.73m capital raising completed by August 2026; FY25 R&D tax incentive of \$478,359 received during FY26.



FY26 Built the Commercial and Organisational Foundations for FY27




US COMMERCIAL MODEL

US wholesale revenue exceeded retail revenue for the first time in June 2026



US DISTRIBUTION

Major distribution partnerships established, with further state -based roll -outs expected through FY27




NEW PRODUCT LAUNCH

1,000 -device iOS LOI with advance payment received; Q1 FY27 launch



NEUROTECH EXPANSION

NeuroStrip expanded across sports performance, rehabilitation and research markets



PLATFORM & ORGANISATION

- NeuroBounce acquired and integrated
- Board strengthened with Stephen Rix as Chairman and Prof Nicholas Opie as Non -Executive Director
- \$9.73m capital raised by August 2026

A Shift from Geographic Retail to a Platform-Led Model

Old Model

Direct / Geographic / Retail



New Model

Platform -led / Wholesale / Distribution / Multiple applications



Assistive Communication

NeuroNode + NextLevel



Neurotech Solutions

Performance + Sport + Rehabilitation



Platform & MedTech

Technology / IP / Connected Devices / Licensing



Three Growth Engines with Different Maturity Profiles

Assistive Communication

Tobii Dynavox, PRC -Saltillo, US state roll -outs, NextLevel and Germany

SCALE

Neurotech Solutions

NeuroStrip, NeuroBounce, Performance, Sport and Rehabilitation

BUILD

Platform & Med Tech

Neural -signal technology, platform partnerships, medical technology and longer -term licensing opportunities

ESTABLISH



FY27 Execution Priorities

Q1

- NextLevel launch
- US distributor ramp continues
- German wholesale distribution agreement

Q2

- US state-based rollout acceleration
- Increasing wholesale contribution
- NeuroStrip commercial expansion
- Apple BCI protocol integration target

Q3

- Early research findings
- European expansion

FY27

- Scale NeuroStrip
- Build recurring revenue channels

- Narrow EBITDA loss
- Progress toward FY28 profitability



Meaningful Progress

WHOLESALE REVENUE— Increasing as a % of total

NEUROSTRIP CLIENTS— 50 already engaged

APP STORE— Regulatory approvals commencing

STROKE LAB— Research collaboration progressing



Independent Clinical Validation in Stroke Rehabilitation



Independent 6 -month clinical validation at STROKE LAB (Tokyo)

- 31 neurological rehabilitation participants
- Integrated into routine clinical care
- Demonstrated clinically actionable insights unavailable from standard assessments

Key Takeaways:

Revealed Hidden Impairments

- Up to 32% lower -limb muscle asymmetry detected in independently walking stroke patients

Phase-specific analysis

- Increased paretic-side engagement identified in 61% of sit-to-stand transitions
- Granular movement insights not available from traditional functional scores

Guided therapy optimisation

Case studies showed:

- 2x increase in paretic muscle activation
- 37% improvement in Timed Up & Go performance
- Up to 71% reduction in compensatory activity

Four unique objective metrics

- Muscle asymmetry
- Activation timing
- Propulsive force generation
- Co-contraction detection

Independent validation confirms NeuroStrip delivers measurable, clinically actionable data in real-world rehabilitation settings, supporting adoption across stroke rehabilitation, neurological care, sports performance and research markets. The Company believes the opportunity in Stroke to be significant. In the US alone there are more than 800,000 individuals who would be appropriate for post-stroke rehab (per Morgan Stanley).

FY27 Revenue Outlook

~50%

expected revenue growth over FY26

Key Assumptions

- US Assistive Communication: growth as Tobii Dynavox and PRC-Salttillo distribution activity ramps
- Australia: modest growth as the ~\$1.1m NDIS order backlog at 30 June 2026 converts through approvals
- NextLevel and Germany: first-year contribution from targeted Q1 launches
- Neurotechnology Solutions: full-year contribution from NeuroStrip and NeuroBounce
- Platform & Med Tech: not assumed to be a material contributor to FY27 revenue growth



FY27: From Building to Scaling

PROFITABILITY PATHWAY

Narrow the EBITDA loss and build the foundations for FY28 profitability

REVENUE

Convert distribution and product launches into material revenue growth

COMMERCIAL MODEL

Establish scalable wholesale and platform -led channels

FY27 is the year we move from building the platform to scaling the platform.



EMPOWERMENT THROUGH PROVEN NEUROTECHNOLOGY

Jeremy Steele —
CEO & Managing Director

Email: jsteele@controlbionics.com

Australia: +61 433 229 470

United States: +1 (855) 831-7521

Website: www.controlbionics.com